AEZS Aeterna Zentaris Inc.

0.89
-0.01  -1%
Previous Close 0.9
Open 0.9
Price To Book -5.93
Market Cap 17,759,318
Shares 19,882,410
Volume 48,651
Short Ratio
Av. Daily Volume 153,783
Stock charts supplied by TradingView

NewsSee all news

  1. Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

    CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Zoptrex
Endometrial cancer

Latest News

  1. Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

    CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective